Oscar Health (NYSE: OSCR) reported second-quarter results that decisively surpassed Wall Street expectations on Thursday, August 6, 2026, yet the stock tumbled approximately 9% during the session — erasing an 8.9% premarket gain. Shares had closed at $30.11 the previous day. Despite the pullback, OSCR remains up roughly 110% year-to-date, far outpacing the S&P 500's 13% advance over the same period.

Q2 Financial Performance

The health insurer posted earnings of $1.10 per diluted share, well above the analyst consensus estimate of 40 cents and a stark reversal from an 89-cent per-share loss in the same period a year earlier. Net income reached $361.8 million.

Total revenue surged 70% year-over-year to $4.88 billion, comfortably beating projections of $4.73 billion. Adjusted EBITDA came in at $415.3 million.

OSCAR HEALTH $OSCR Q2'26 EARNINGS HIGHLIGHTS
Revenue: $4.9B (Est. $4.75B) EPS: $1.10 (Est. $0.39) Adj EBITDA: $415.3M (Est. $188M) Net Income: $361.8M (Est. $156M)
FY26 Guide: Revenue: $18.7B-$19.0B (Est. $18.62B) Operating Income: $500M-$700M… pic.twitter.com/DSJfXJ4Nd4
— Wall St Engine (@wallstengine) August 6, 2026

For the first six months of 2026, Oscar generated net income of $1.04 billion, or $3.16 per share — a dramatic increase from the $46.9 million recorded during the comparable period in 2025.

Medical Loss Ratio Improvement and Raised Guidance

Oscar's medical loss ratio improved markedly to 79.2% in the second quarter, down from 91.1% in Q2 2025 and better than the Street's 81.2% forecast. Management credited the gains to pricing discipline and $164 million in favorable adjustments to prior-period reserves.

The company raised its full-year operating earnings outlook to a range of $500 million to $700 million, up from the prior guidance of $250 million to $450 million. Total revenue guidance was maintained at $18.7 billion to $19 billion, giving investors a clearer read-through on how management is balancing growth with profitability in a market that has become more competitive for ACA plans.

Membership Growth Against Industry Headwinds

Oscar's membership base stood at 2.9 million as of June 30, representing 46% year-over-year growth. This expansion came even as nationwide Affordable Care Act (ACA) enrollment contracted by approximately three million members after temporary federal subsidies expired late last year.

Major competitors have retreated from the ACA individual marketplace: CVS Health's Aetna withdrew this year, and Cigna announced plans to exit in 2027. Oscar has taken the opposite approach by deepening its presence, making its results a useful gauge of whether smaller, ACA-focused insurers can keep scaling while larger peers step back.

Membership Attrition Concerns Weigh on Sentiment

Stephens analyst Raj Kumar identified potential membership attrition in the second half of the year as a likely factor behind the sell-off. Enrollment had already dipped modestly, from 3.2 million at the end of March to 2.96 million by June 30.

During the earnings call, CEO Mark Bertolini acknowledged expectations for "further market contraction" going forward. Kumar noted that continued attrition "could add additional risk" to the company's outlook. Unlike larger, more diversified insurers, Oscar derives essentially all of its revenue from the ACA marketplace, so shifts in enrollment mix and retention can have an outsized effect on results.

Baird analyst Michael Ha called the results "an important proof point for the earnings thesis," while cautioning that holding the stock requires conviction that the ACA marketplace "remains structurally viable as enrollment and market composition evolve."

The consensus analyst rating on OSCR is Hold, with a mean price target of $26.09 according to FactSet data — below the share price at which the stock traded prior to Thursday's decline.

Bertolini expressed confidence about the path ahead, stating the company enters the second half of 2026 "from a position of strength, with the technology, scale, and operating discipline to deliver profitable growth."